Jean A. Maroun

13.8k total citations · 4 hit papers
136 papers, 9.6k citations indexed

About

Jean A. Maroun is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jean A. Maroun has authored 136 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Oncology, 49 papers in Pulmonary and Respiratory Medicine and 25 papers in Molecular Biology. Recurrent topics in Jean A. Maroun's work include Colorectal Cancer Treatments and Studies (67 papers), Cancer Treatment and Pharmacology (43 papers) and Gastric Cancer Management and Outcomes (25 papers). Jean A. Maroun is often cited by papers focused on Colorectal Cancer Treatments and Studies (67 papers), Cancer Treatment and Pharmacology (43 papers) and Gastric Cancer Management and Outcomes (25 papers). Jean A. Maroun collaborates with scholars based in Canada, United States and United Kingdom. Jean A. Maroun's co-authors include John V. Cox, Eric Van Cutsem, Malcolm J. Moore, Craig C. Earle, Charles D. Blanke, Lee S. Rosen, Leonard B. Saltz, Stephen P. Ackland, Gary Elfring and Nicoletta Pirotta and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jean A. Maroun

135 papers receiving 9.2k citations

Hit Papers

4 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

2000 2.4k citations Malcolm J. Moore, Jean A. Maroun et al. profile →
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer

2004 1.1k citations A Figueredo, Jean A. Maroun et al. Journal of Clinical Oncology profile →
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study

2001 882 citations Gerald Batist, Jean A. Maroun et al. Journal of Clinical Oncology profile →
Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer

2011 533 citations Daniel G. Haller, Josep Tabernero et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jean A. Maroun Canada	35	7.4k	2.6k	2.1k	1.7k	1.4k	136	9.6k
Jim Cassidy United Kingdom	42	9.4k 1.3×	3.1k 1.2×	2.3k 1.1×	1.5k 0.9×	1.5k 1.1×	122	11.7k
Harry Bleiberg Belgium	40	7.2k 1.0×	4.2k 1.6×	2.5k 1.2×	1.4k 0.9×	1.7k 1.1×	163	10.2k
H. Cortés-Funes Spain	44	6.4k 0.9×	2.6k 1.0×	2.1k 1.0×	872 0.5×	1.8k 1.2×	192	9.6k
Christophe Tournigand France	42	7.0k 0.9×	3.0k 1.1×	2.4k 1.2×	1.2k 0.7×	949 0.7×	256	9.5k
Eduardo Díaz‐Rubio Spain	49	8.7k 1.2×	3.5k 1.3×	2.4k 1.1×	1.9k 1.1×	2.0k 1.4×	351	12.0k
Cynthia G. Leichman United States	30	4.6k 0.6×	2.0k 0.8×	1.7k 0.8×	1.2k 0.7×	1.5k 1.0×	64	6.2k
Matilde Navarro Spain	27	8.2k 1.1×	2.2k 0.8×	2.2k 1.1×	2.1k 1.3×	1.6k 1.1×	75	9.9k
Alberto Zaniboni Italy	40	6.3k 0.8×	2.5k 0.9×	1.5k 0.7×	1.9k 1.1×	1.1k 0.8×	301	8.1k
C. Boni Italy	34	11.0k 1.5×	5.5k 2.1×	3.3k 1.6×	2.1k 1.3×	1.7k 1.2×	122	13.9k
Scott Wadler United States	43	4.5k 0.6×	1.9k 0.7×	1.9k 0.9×	975 0.6×	2.0k 1.4×	192	8.1k

Countries citing papers authored by Jean A. Maroun

Since Specialization

Citations

This map shows the geographic impact of Jean A. Maroun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean A. Maroun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean A. Maroun more than expected).

Fields of papers citing papers by Jean A. Maroun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean A. Maroun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean A. Maroun. The network helps show where Jean A. Maroun may publish in the future.

Co-authorship network of co-authors of Jean A. Maroun

This figure shows the co-authorship network connecting the top 25 collaborators of Jean A. Maroun. A scholar is included among the top collaborators of Jean A. Maroun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean A. Maroun. Jean A. Maroun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maroun, Jean A., Petr Kavan, M. Christine Cripps, et al.. (2014). Standard Clinical Practice of Folfirinox (Ffx) in Advanced/Metastatic Pancreatic Cancer (Pc) Patients: a Canadian Retrospective Registry. Annals of Oncology. 25. iv238–iv238. 4 indexed citations

Haller, Daniel G., Josep Tabernero, Jean A. Maroun, et al.. (2011). Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer. Journal of Clinical Oncology. 29(11). 1465–1471. 533 indexed citations breakdown →

Sherman, Morris, Kelly W. Burak, Jean A. Maroun, et al.. (2011). Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Current Oncology. 18(5). 228–240. 48 indexed citations

Vickers, Michael M., Jair Bar, Nirit Yarom, et al.. (2011). Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. Clinical & Experimental Metastasis. 29(2). 123–132. 99 indexed citations

Gill, Sharlene, Scott Berry, James Biagi, et al.. (2011). Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer. Current Oncology. 18(0). S5–S10. 21 indexed citations

Maroun, Jean A.. (2011). The significance of progression-free survival as an endpoint in evaluating the therapeutic value of antineoplastic agents. Current Oncology. 18(S2). S3–4. 3 indexed citations

Maroun, Jean A., et al.. (2010). Cost-Effectiveness of Oxaliplatin in the Adjuvant Treatment of Colon Cancer in Canada. Current Oncology. 17(1). 17–24. 20 indexed citations

Maroun, Jean A., Lowell Anthony, Normand Blais, et al.. (2007). Prevention and Management of Chemotherapy-Induced Diarrhea in Patients with Colorectal Cancer: A Consensus Statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Current Oncology. 14(1). 13–20. 109 indexed citations

Shah, Amil M., et al.. (2005). Surrogate Endpoints in Colorectal Cancer. Current Oncology. 12(4). 136–146. 1 indexed citations

10.

Figueredo, A, R. Bryan Rumble, Jean A. Maroun, et al.. (2003). Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 3(1). 26–26. 280 indexed citations

11.

Hedley, David W., Amit M. Oza, Ronald Feld, et al.. (2002). The Palliative Benefit of Irinotecan in 5-Fluorouracil—Refractory Colorectal Cancer: Its Prospective Evaluation by a Multicenter Canadian Trial. Clinical Colorectal Cancer. 2(2). 93–101. 15 indexed citations

12.

Bjarnason, Georg A., C. Cripps, Rakesh Goel, et al.. (1998). Phase I-II Study of 5-Fluorouracil, Leucovorin, Doxorubicin, Methotrexate, and Long-Term Oral Etoposide (FLAME) in Unresectable or Metastatic Gastric Cancer. American Journal of Clinical Oncology. 21(6). 537–542.

13.

Moore, Malcolm J., Jean A. Maroun, Francisco Robert, et al.. (1993). Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer. Investigational New Drugs. 11(1). 61–65. 38 indexed citations

14.

Maroun, Jean A., John C. Ruckdeschel, Ronald B. Natale, et al.. (1993). Multicenter phase II study of brequinar sodium in patients with advanced lung cancer. Cancer Chemotherapy and Pharmacology. 32(1). 64–66. 58 indexed citations

15.

Maroun, Jean A., et al.. (1993). Phase II study on DuP 937 (Teloxantrone) in colorectal carcinoma. Investigational New Drugs. 11(2-3). 235–237. 4 indexed citations

16.

Maroun, Jean A. & David J. Stewart. (1990). Phase I study of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Investigational New Drugs. 8(S1). S33–S39. 9 indexed citations

17.

Maroun, Jean A., et al.. (1988). Trimetrexate combined with cisplatin or etoposide in the treatment of non-small cell lung cancer: a pilot study.. PubMed. 15(2 Suppl 2). 38–40. 6 indexed citations

18.

Stewart, David J., Shailendra Verma, & Jean A. Maroun. (1987). Phase I Study of the Combination of Disulfiram with Cisplatin. American Journal of Clinical Oncology. 10(6). 517–519. 14 indexed citations

19.

Maroun, Jean A., et al.. (1986). Neurotoxicity and efficacy of combined vinca alkaloids in breast cancer. Journal of Ethnopharmacology. 18(3). 299–299. 2 indexed citations

20.

Stewart, David J., Norman G. Futter, Jean A. Maroun, et al.. (1984). Intra-Arterial Cisplatin Treatment of Unresectable or Medically Inoperable Invasive Carcinoma of the Bladder. The Journal of Urology. 131(2). 258–260. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact